The short version
- Why people research itMitochondrial repair and efficient ATP production (FDA accelerated approval for Barth syndrome, Sep 2025; other uses still in trials).
- What the evidence isReal, registered human trials — and the most instructive mixed record in the Vault.
- What to watchHard, hot or spreading skin at an injection site.
How SS-31 works
SS-31 does not scavenge a free radical, does not donate an electron, and does not enter the mitochondrion because of the membrane potential. It binds a lipid.
The molecule. SS-31, developed as elamipretide, is a tetrapeptide with an alternating aromatic-cationic motif: D-Arg-Dmt-Lys-Phe-NH2, where Dmt is 2',6'-dimethyltyrosine. Three features matter.
- Injectable
- Nasal
On the goal map: Mitochondrial ATP production (Energy & fatigue)
Research on SS-316 evidence notes: clinical, correlative, mechanism
Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work
Evidence on file: FDA accelerated approval for Barth syndrome (Forzinity, Sep 2025); other uses still in trials.
Human clinical evidence
Real, registered human trials — and the most instructive mixed record in the Vault. Elamipretide (the drug name for SS-31) has been through multiple phase 2 and phase 3 programs in primary mitochondrial myopathy, Barth syndrome and dry AMD.
MMPOWER-3 in primary mitochondrial myopathy missed its primary endpoint — six-minute walk distance. What that miss means is worth being careful about. Primary mitochondrial myopathy is an umbrella over dozens of distinct genetic defects, and a walk test is a blunt instrument for a population that heterogeneous; the earlier MMPOWER-2 crossover had shown a signal on the same measure, and patient-reported fatigue moved in the direction of benefit.
The Barth syndrome program — a single, defined cardiolipin-remodeling defect, which is exactly what the mechanism targets — reported functional improvement, and on 19 September 2025 the FDA granted accelerated approval to Forzinity (elamipretide) injection for Barth syndrome in patients weighing at least 30 kg, on improved knee-extensor muscle strength, with a confirmatory placebo-controlled trial required (FDA, 19 Sep 2025). It is the first drug approved for Barth syndrome. That contrast is the actual lesson: the compound did better in the population its mechanism predicts, and worse in the one that was mostly a diagnostic category.
Correlative data
Research-community use for mitochondrial and recovery goals. Reported experience is subtle — as expected for something targeting an organelle rather than a symptom.
How the mechanism reads
A tetrapeptide that concentrates in the inner mitochondrial membrane and binds cardiolipin — the phospholipid that organizes the electron transport chain. Stabilizing cardiolipin is proposed to improve ATP production and reduce electron leak.
MechanisticThe mechanism predicts where it should work best: tissues where mitochondrial dysfunction is the actual bottleneck. That is also why the trials succeeded in a rare cardiolipin-remodeling disease and struggled in broader populations.
Mechanistic
Sources
- Tung C, et al. Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential. International Journal of Molecular Sciences 2025 · PMID 39940712
- Sabbah HN. Contemporary insights into elamipretide's mitochondrial mechanism of action and therapeutic effects. Biomedicine and Pharmacotherapy 2025 · PMID 40294492
- Roshanravan B, et al. PLOS ONE 2021 · PMID 34264994
- Reid Thompson W, et al. A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism. Genetics in Medicine 2021 · PMID 33077895
- Zhu Y, et al. SS-31, a Mitochondria-Targeting Peptide, Ameliorates Kidney Disease. Oxidative Medicine and Cellular Longevity 2022 · PMID 35707274
SS-31 safety basicsWho should avoid it, what to expect, what to watch
Avoid if
- Active cancer: restoring mitochondrial ATP efficiency also helps tumor cells.
- Hypersensitivity to elamipretide or its formulation.
- Pregnancy or breastfeeding: no data outside Barth syndrome trials.
- Bleeding disorder or anticoagulant use: repeated injections bruise more.
What’s expected
- Injection-site reactions are common with this peptide.
- Less fatigue and better exercise tolerance if cardiolipin repair works for you.
- Mild headache while using SS-31.
Watch for
- Hard, hot or spreading skin at an injection site.
- Hives or breathlessness.
- Palpitations or new heart failure signs.
- Fever while using SS-31.
Labs that tell you it’s working
- Coenzyme Q10
- Carnitine, Total and Free
- High-Sensitivity Troponin T
- Comprehensive Metabolic Panel (CMP)
Elamipretide binds cardiolipin to stabilize inner-membrane cristae; it is approved for Barth syndrome, and mitochondrial and cardiac labs track effect. PMID 33077895 PMID 39940712
Bloodwork to runHow you would know it is working: 9 tests in one order, code CAMERON
A panel picked from how it works and what it can move: the tests, and why each is on it.
Code CAMERON applies automatically. The before and after schedule and how to read the results are in the Skool lesson.
SS-31 FAQ4 common questions
- Is SS-31 approved for human use?
- SS-31 is an approved medicine for the uses on its label. This page covers research beyond those uses, as education, not medical advice.
- What is SS-31 researched for?
- Mitochondrial repair and efficient ATP production (FDA accelerated approval for Barth syndrome, Sep 2025; other uses still in trials).
- Which labs show whether it's doing anything?
- Coenzyme Q10; Carnitine, Total and Free; High-Sensitivity Troponin T; Comprehensive Metabolic Panel: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
- Where's the full protocol?
- In the Skool lesson for SS-31: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.





